ERBB2 and neoplasm: PRS-343 is a bispecific antibody-anticalin fusion protein that targets HER2 and 4-1BB, aiming to overcome these limitations and avoid unnecessary peripheral toxicity by activating 4-1BB in a tumor-specific manner [67].